Eli Lilly teams with Amplitude on taRNA vaccine platform as Otsuka ends psychedelic trial
read at Endpoints ↗DealNeutral
Eli Lilly announced a collaboration with Amplitude Therapeutics to co‑develop vaccine candidates using a trans‑amplifying RNA (taRNA) platform.
The taRNA approach aims to boost antigen expression while using lower doses of RNA, which could improve manufacturing efficiency and immune response.
In separate news, Otsuka Pharmaceutical said it is halting its clinical program testing a psychedelic compound, ending the trial after internal review.
The briefing also noted updates from AC Immune, Lilly’s gene‑therapy unit Adverum, and SiranBio, but no further details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trial”
read at Endpoints ↗75 words · retrieved Aug 20
comments(0)
5-min edit window · permanent after that